Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).Robert Wesolowski, Bhuvaneswari Ramaswamy, Ewa Mrózek et al.|Journal of Clinical Oncology|2014Cited by 16
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker StudyRobert Wesolowski, Bhuvaneswari Ramaswamy, Daniel G. Stover et al.|The Oncologist|2020Cited by 14